Saint Prex, Switzerland – 20 March, 2017 – Ferring Pharmaceuticals and CD Investments (CDI) announced today that they have signed an agreement granting Ferring exclusive European marketing rights to CDI’s VSL#3®. This agreement extends Ferring’s existing rights to market the product in the UK, Italy and Canada.